News
This shift follows the announcement of initial positive data from the Phase 1/2 clinical trial of PM359 in Chronic ...
NEBRASKA MEDICINE Michael Ash, MD Kyle Skiermont, Pharm D Michael Ash, MD, officially began his role as CEO of Nebraska ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback